Vor Biopharma Inc: 10% owner RA Capital exercised 500 shares

What happened

• RA Capital Management, L.P., a 10% owner, exercised options to acquire 500 shares of Vor Biopharma common stock at $12.80 per share on Oct 2, 2026, for a total of $6,400. The same filing reports a related disposal of 500 shares reported at $0.00 as a derivative transaction on Oct 2, 2026.

Key details

• Transaction date(s) and price(s): Oct 2, 2026 — exercised 500 shares @ $12.80 (code M) for $6,400; Oct 2, 2026 — disposed 500 shares @ $0.00 (derivative).
• Shares owned after the transaction: held directly by the Fund (see footnote F4); exact post-transaction count is not stated in the filing.
• Relevant footnotes:
  • F1: RA Capital is the investment manager for the Fund and disclaims beneficial ownership except for pecuniary interest.
  • F2: the option was granted to Andrew Levin for the benefit of the Fund; Levin must turn over any stock received to the Adviser to offset advisory fees.
  • F3: prior transfers between the Adviser and the Fund reflected a change in form of ownership and were not required to be reported.
  • F4: shares are held directly by the Fund.
  • F5: option was immediately exercisable.
• Filing date: filed Oct 5, 2026 for transactions on Oct 2, 2026.

Why it may matter

• The filing reports exercised options; the $12.80 exercise indicates a paid exercise rather than a cashless exercise.
• The $0.00 derivative disposition appears tied to the Fund/Adviser transfer arrangement described in the footnotes and is not a market sale.
• RA Capital Management is a 10% owner (an investment manager), not an executive officer. A filing does not show why the insider traded or why the company acted.